ABBV - Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

• Oncternal Therapeutics ( NASDAQ: ONCT ) on Thursday said it had entered into a clinical trial collaboration with AbbVie ( ABBV ) company Pharmacyclics to support its phase 3 lymphoma study.
• ONCT stock gained ~9% to $1.22 after hours.
• As per the terms of the collaboration, Pharmacyclics will supply its lymphoma medicine ibrutinib for ONCT's late-stage trial.
• ONCT's late-stage trial, called ZILO-301, is evaluating the company's monoclonal antibody zilovertamab in combination with ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma, a rare type of cancer of the lymphatic system.
• The agreement also includes the supply of ibrutinib for ZILO-302, an open-label companion study of zilovertamab plus ibrutinib for patients who have progressive disease during the initial four months of ibrutinib monotherapy from the ZILO-301 study.
• Pharmacyclics' ibrutinib is FDA approved under the brand name Imbruvica for the treatment of various types of lymphoma and leukemia.

For further details see: